---
title: "AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297481701.md"
description: "Repatha, the sole PCSK9 inhibitor, has demonstrated a reduction in the risk of all-cause mortality, along with cardiovascular events, in high-risk primary prevention patients during a Phase 3 trial. Global real-world analyses have highlighted ongoing deficiencies in lipid management, indicating significant gaps in care for numerous high-risk individuals."
datetime: "2026-08-31T07:45:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297481701.md)
  - [en](https://longbridge.com/en/news/297481701.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297481701.md)
generator: "portal-rs"
---

# AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE

Repatha, the sole PCSK9 inhibitor, has demonstrated a reduction in the risk of all-cause mortality, along with cardiovascular events, in high-risk primary prevention patients during a Phase 3 trial. Global real-world analyses have highlighted ongoing deficiencies in lipid management, indicating significant gaps in care for numerous high-risk individuals.

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [UK regulator suspends Amgen's Tavneos for new patients over unreliable data](https://longbridge.com/en/news/297642592.md)
- [Strait & Sound Wealth Management LLC Invests $1.92 Million in Amgen Inc. $AMGN](https://longbridge.com/en/news/297400046.md)
- [8,321 Shares in Amgen Inc. $AMGN Bought by Glenview Trust Co](https://longbridge.com/en/news/297400065.md)
- [Milestone Pharmaceuticals study finds PSVT curbs daily activities, drives anxiety between episodes](https://longbridge.com/en/news/297181539.md)
- [Alnylam announces new data at ESC Congress on AMVUTTRA](https://longbridge.com/en/news/297453980.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**